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Abstract
Background: One of the new roles for enzymes in personalized medicine builds on
a rational approach to cancer biomarker discovery using enzyme-associated aberrant
glycosylation. A hallmark of cancer, aberrant glycosylation is associated with
differential expressions of enzymes such as glycosyltransferase and glycosidases.
The aberrant expressions of the enzymes in turn cause cancer cells to produce
glycoproteins with specific cancer-associated aberrations in glycan structures.
Content: In this review we provide examples of cancer biomarker discovery using
aberrant glycosylation in three areas. First, changes in glycosylation machinery such
as glycosyltransferases/glycosidases could be used as cancer biomarkers. Second,
most of the clinically useful cancer biomarkers are glycoproteins. Discovery of specific
cancer-associated aberrations in glycan structures of these existing biomarkers could
improve their cancer specificity, such as the discovery of AFP-L3, fucosylated
glycoforms of AFP. Third, cancer-associated aberrations in glycan structures provide a
compelling rationale for discovering new biomarkers using glycomic and
glycoproteomic technologies.
Summary: As a hallmark of cancer, aberrant glycosylation allows for the rational
design of biomarker discovery efforts. But more important, we need to translate
these biomarkers from discovery to clinical diagnostics using good strategies, such as
the lessons learned from translating the biomarkers discovered using proteomic
technologies to OVA 1, the first FDA-cleared In Vitro Diagnostic Multivariate Index
Assay (IVDMIA). These lessons, providing important guidance in current efforts in
biomarker discovery and translation, are applicable to the discovery of aberrant
glycosylation associated with enzymes as cancer biomarkers as well.
Keywords: Enzyme, Aberrant Glycosylation, Cancer Biomarkers, Glycosyltransferases,
Glycoprotein, Glycan
Introduction
Enzymes were one of the first protein molecules used as cancer biomarkers. Discov-
ered in the early 1980s as a cancer biomarker for the early detection of prostate cancer,
prostate specific antigen (PSA) is a serine protease[1]. With the exception of PSA, the
increase in enzymatic activities or protein mass is not sensitive or specific enough for
early detection of cancer[1]. Nevertheless, enzymes as cancer biomarkers have pro-
found clinical utilities in the personalized approach to cancer diagnosis and treatment:
Her-2/neu, a cell membrane surface-bound receptor tyrosine kinase, is a predictive
marker to select breast cancer patients for treatment with trastuzumab (Herceptin)
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for newly diagnosed breast cancer patients with lymph node-negative disease[4,4-7].
During the last decade, proteomic technologies have provided a new approach to
identifying enzymes and related proteins as cancer biomarkers[8]. Glycoproteomic
technologies that study glycans and glycoproteins are of particular interest in this
regard because (1) aberrant glycosylation is a hallmark of cancer, reflecting cancer-spe-
cific changes in glycan biosynthesis pathways such as expression of glycosyltransferases
and glycosidases[9-13] and (2) aberrant expression of these enzymes causes cancer
cells to produce glycolipids and glycoproteins with modified glycans[12]. Advance-
ments in glycoproteomic technologies have enabled comprehensive analyses of a given
cell type or organism of all the glycan structures (glycomics) and of all the proteins
containing glycans (glycoproteomics). Exploiting the difference in glycans between can-
cer and normal cells provides opportunities to discover new biomarkers for persona-
lized cancer diagnosis and treatment. Discovery of these cancer-associated
modifications of glycans on the glycoproteins may also improve on the specificity of
existing cancer biomarkers. The feasibility of this approach has been demonstrated in
the story of alpha-fetoprotein (AFP), a marker for hepatocellular carcinoma (HCC).
AFP is not HCC-specific. Elevation of serum AFP levels also occurs in non-HCC con-
ditions such as pregnancy, hepatitis, and liver cirrhosis[1]. In contrast, AFP-L3, consist-
ing of core-fucosylated glycoforms of AFP, provides better specificity for HCC[14]. The
improved cancer specificity of AFP-L3 is due to HCC’s over-expression of enzyme
fucosyltransferase Fut 8, which is required to produce core-fucosylated AFP and other
enzymes pivotal for the synthesis of GDP-fucose, the substrate of the fucosyltransferase
[15-18].
In this review, we provide examples of cancer biomarker discovery using aberrant
glycosylation in three areas: (1) glycosyltransferases/glycosidases as cancer biomarkers,
(2) improving on existing cancer biomarkers and, (3) discovery of new cancer biomar-
kers using glycomic and glycoproteomic approaches. We discuss the potential clinical
applications of these biomarkers such as detection, prediction, and prognosis for a par-
ticular type of cancer. These types of clinical applications may be sufficient for a bio-
marker in the discovery phase; however, for a biomarker intended for clinical
diagnosis, it would be better to define the clinical application at a specific decision-
making point along the disease progression path[19].
Glycosyltransferases/glycosidases as cancer biomarkers
Although multiple factors contribute to aberrant glycosylation in cancer–such as the
availability and localization of nucleotide sugar donors and substrates–one of the pri-
mary mechanisms seems to be the differential expression of glycosyltransferases and
glycosidases involved in the synthesis and catabolism of glycans. Therefore, these
enzymes themselves may be used as cancer biomarkers (Table 1). The first example of
such biomarkers is a family of enzymes that regulate the initial steps of mucin O-gly-
cosylation: UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltrans-
ferases (ppGalNAc-T). Genome-wide association studies have shown that one single-
nucleotide polymorphism (SNP) in GALN T 1 ,t h eg e n ee n c o d i n gap p G a l N A c - T
enzyme, was statistically significant and inversely associated with the risk of ovarian
cancer[20]. Furthermore, enzymes from this family of GALNT6 and GALNT14 were
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sue biomarkers[21-25]. Because aberrant glycoproteins as a result of these enzymes may
be involved in promoting tumor invasion and metastasis, these enzymes could also be
used as therapeutic targets. For example, screening for GALNT6 inhibitors would be
valuable for development of novel therapeutic modalities against breast cancer, since
over-expression of GALNT6 might contribute to mammary carcinogenesis [24].
Another glycosyltranferase that may be used as a cancer biomarker is UDP-N-acetyl-
D-glucosamine: N-acetylglucosamine transferase V (GlcNAcT-V) that is responsible
for b1-6 branching of N-glycans. Increased b1-6 branching of N-glycans as a result of
over-expression of GlcNAcT-V in cancer plays an important role in tumor metastasis.
Increased b1-6 branched N-glycans have been associated with lymph node metastasis
in breast carcinoma[26]. Increased b1-6 branching of target proteins of GlcNAcT-V
such as cadherin, integrin, and other cytokine receptors may enhance and promote
tumor growth and metastasis[27-29]. Furthermore, Granovsky et al.[30] have shown
that polyomavirus middle T antigen (PyMT)-induced tumor growth and metastasis
were suppressed in adult mice lacking GlcNAcT-V. Thus, over-expression of
GlcNAcT-V in cancer could be used as a biomarker of cancer progression and
metastasis.
Sialyltransferases are another family of glycosyltranferases that are not only abnor-
mally expressed in cancers[31-34], but are also implicated in carcinogenesis, progres-
sion, and metastasis. Over-expression of a 2-3 sialyltranferase I (ST3Gal-I) promotes
mammary tumorigenesis in transgenic mice th a to v e r - e x p r e s st h i se n z y m eu n d e rt h e
control of the MUC1 promoter[35]. The over-expression of a 2-3 sialyltranferase III
(ST3Gal-III) in pancreatic cancer cell lines indicates its roles in tumor progression[36].
Expression of a 2-6 sialyltransferase I (ST6GalNAc-I) in MDA-MB-231 breast cancer
cells enhances the tumorigenicity of breast cancer cells[37]. Over-expression of sialyl-
transferases is generally associated with cancer progression and poor patient survival
[22,38,39]. For example, over-expression of ST6GalNAc-II is related to poor patient
survival in colorectal carcinomas as determined by reverse transcription PCR in 40
cases of colorectal carcinoma specimens and in “normal” mucosa of the same patients
[40]. Interestingly, a 2-6 sialyltransferase I (ST6GalNAc-I) was associated with better
prognosis in breast cancer in a study that compared mRNA levels of ST6GalNAc-I
genes in 127 breast cancer tissues to 33 normal background tissues[22].
In addition to the role of tissue glycosyltransferases and glycosidases for risk assess-
ment and prognosis, these enzymes may also be used as serum biomarkers for early
detection of cancer and prediction of treatments. Ishizuka et al.[41] have shown that
serial determination of serum a-L-fucosidase activity could be used for predicting the
development of HCC in patients with liver cirrhosis–even before the detection of HCC
Table 1 Enzymes associated with aberrant glycosylation as cancer biomarkers
Enzyme Short form Implication in aberrant glycosylation
polypeptide
N-acetylgalactosaminyltransferase
ppGalNAc-T Increased incomplete systhesis of
O-glycans
N-acetylglucosamine transferase V GlcNAcT-V Increasedb1-6 branching of N-glycans
a 2-3 sialyltransferases ST3Gal I, ST3 Gal IV Increased expression of sialylated glycans
a 2-6 sialyltransferase ST6GalNAc
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activity was significantly correlated with progression-free survival in 24 breast cancer
patients treated with trastuzumab monotherapy. Such activity indicates that it could be
a predictive biomarker of sensitivity to trastuzumab treatment of breast cancer
patients.
Improving on Existing Cancer Biomarkers
Most of the U.S. Food and Drug Administration (FDA)-approved cancer biomarkers
are glycoproteins. Discovery of the glycoforms related to cancer may help improve on
these cancer biomarkers. Such endeavors require knowledge of whether carbohydrates
on these proteins contribute to their use as cancer biomarkers. Since these biomarkers
are measured by immunoassays, it would be important to understand whether antibo-
dies used in these diagnostic tests are carbohydrate dependent. Based on the antibo-
dies, clinically used cancer biomarkers can be divided into two groups: (1)
carbohydrate-independent such as PSA, and (2) carbohydrate-dependent. Carbohy-
drate-dependent biomarkers can be further divided into two groups: (1) protein bio-
markers such as CA 15-3/CA 27.29 and CA125, and (2) glycan markers such as CA
19-9. We discuss current research and potential ways to improve on biomarkers using
PSA, CA 15-3/CA 27.29 and CA125, and CA 19-9 as examples.
PSA
PSA is a proteolytic enzyme synthesized almost exclusively by the prostate. Under nor-
mal physiological conditions PSA concentrations in blood are low. However, under
pathological conditions associated with the prostate–prostate cancer, prostitis, benign
prostatic hyperplasia (BPH), and prostatic intraepithelial neoplasia–PSA concentrations
in blood become elevated. Although elevation of serum PSA has been used clinically as
a biomarker to help detect prostate cancer, it is not prostate cancer specific. The mole-
cular isoforms of PSA such as free PSA and [-2] proenzyme PSA show moderate
improvement in cancer specificity over PSA[1,43].
The antibodies currently used for measurement of PSA in diagnostic tests are carbo-
hydrate-independent. As a result, current immunoassays for PSA are carbohydrate
independent. However, PSA is a glycoprotein and has different glycoforms. Measure-
ment of cancer-associated glycoforms of PSA may help improve the cancer specificity
of PSA. Peracaula et al. [44] initially demonstrated this possibility–that altered glycosy-
lation patterns allow the distinction of PSA from seminal fluid (normal) and prostate
cancer LNCaP cells (tumor origins). Then, several glycoforms of PSA in serum to dis-
tinguish patients with prostate cancer from those with BPH were discovered: differen-
tial binding of PSA in serum to Maackia amurensis (MAA), a lectin that recognizes
terminal a2-3 sialylation, by Ohyama et al.[45], and alpha1,2-fucosylated and beta-N-
acetylgalactosaminylated PSA, by Fukushima et al.[46]. Furthermore, Meany et al.
reported that Sambucus nigra (SNA)-bound PSA may improve on the percent free
PSA in the diagnostic gray zone of percent free PSA between 10% and 20% in a subset
of 21 patients (11 cancer and 10 non-cancer) and in a separate study of 16 additional
subjects (8 cancer and 8 non-cancer)[47].
Aberrant glycoforms of PSA may help detect aggressive prostate cancers. Currently,
aggressive and non-aggressive prostate cancers may all be initially diagnosed as
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cancers are alike. Some are non-aggressive; even if left untreated, they neither reduce
q u a l i t yo fl i f en o rp r o g r e s st oc a u s em o r t a l i t y .S o m ea r ea g g r e s s i v ea n da th i g h e rr i s k
for recurrence after treatment or death from prostate cancer. Current methodologies
(e.g., PSA, biopsy, and tumor staging) cannot accurately differentiate patients with
aggressive or non-aggressive cancers. Thus we urgently need new biomarkers that
accurately make this distinction at initial diagnosis of prostate cancer to allow each
subgroup to receive the most appropriate therapy. In testing the hypothesis that aber-
rant glycoforms of PSA may help detect aggressive prostate cancers, we studied 13
individual glycan profiles of PSA enriched from prostate tissue specimens: 2 normal
(N), 3 normal tissues from prostates with non-aggressive tumors (NAN), 3 cancerous
tissues from the same prostates as NAN (NAT), 3 normal tissues from prostates with
aggressive tumors (AN), and 2 cancerous tissues from the same prostates as AN (AT).
Lectins Maclura pomifera (MPA) and Ulex europaeus ( U E A )s h o w e dat r e n do f
increased binding to PSA enriched from prostate tissue with increasing tumor aggres-
siveness. UEA was able to distinguish normal PSA in prostates with non-aggressive
tumors from aggressive tumors (NAN vs. AN, p < 0.05). Therefore, aberrant glyco-
forms of PSA may help detect aggressive forms of prostate cancer.
CA 15-3/CA 27.29 and CA125
Polymorphic epithelial mucin (MUC 1) is a highly O-glycosylated transmembrane gly-
coprotein, produced on the apical surfaces of the lining of hollow organs and glands
toward the lumen by mucosal epithelial cells. Malignant transformation of mucosal
epithelia causes MUC 1 to enter the bloodstream aberrantly. Measurement of MUC 1
in blood, therefore, serves as a guide for detecting and monitoring cancer. CA 15-3
and CA 27.29 are FDA-approved assays for the measurement of circulating MUC 1
antigen as an aid in monitoring disease recurrence or response to therapy in patients
previously diagnosed with breast cancer. The most clinical utility of CA 15-3/CA 27.29
is in the setting of monitoring therapy in patients with advanced breast cancer through
serial determinations of CA 15-3/CA 27.29 in conjunction with diagnostic imaging,
history, and physical exams. Although high preoperative levels of CA 15-3/CA 27.29
are associated with adverse patient outcomes, CA 15-3/CA 27.29 has not been recom-
mended by the National Academy of Clinical Biochemistry (NACB) or the American
Society of Clinical Oncology (ASCO) for management of early stages of breast cancer,
nor has it been recommended for detecting recurrence after primary breast cancer
therapy–despite the fact that serial determination of CA 15-3/CA 27.29 levels after pri-
mary or adjuvant therapy can predict recurrence an average of 5-6 months before
other symptoms or tests[49]. Finally, CA 15-3/CA 27.29 should not be used for early
detection of breast cancer, due to a lack of sensitivity and specificity.
As a tumor marker for ovarian cancer, CA 125 is a MUC16 glycoprotein comprised
of a carboxyl terminus anchor region, a dominant repeat region, and a predominantly
O-glycosylated region. First described by Bast et al.[50] in 1981, CA125 is defined by
the mouse monoclonal antibody OC 125, which recognizes the surface of ovarian
tumor cells. Anchored to the epithelium by a transmembrane domain, CA125 is
released to the extracellular space by enzymatic cleavage. Measurement of CA125 in
blood, therefore, serves as an aid in monitoring disease recurrence or response to
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CA125 alone lacks the sensitivity and specificity needed for screening asymptomatic
women, it remains the single-best biomarker available for ovarian cancer[51-53].
Discovery of cancer-associated glycoforms of circulating MUC 1 and MUC 16 anti-
gens may help improve their specificity for breast and ovarian cancers, respectively.
Storr et al.[54] analyzed the O-glycans of MUC1 from the serum of a breast cancer
patient and found them to be comprised mainly of sialylated core 1 type glycans. Jan-
kovic et al.[55] compared glycans of CA-125 (MUC16) isolated from amniotic fluid to
the CA-125 from an OVCAR3 ovarian cancer cell line. They found a significant
increase in the reactivity of OVCAR3 CA-125 with the lectin E-PHA compared with
CA-125 from amniotic fluid. Once the cancer-associated glycan structure is identified,
antibodies that specifically target the structure may be developed for improving on the
current diagnostic tests.
CA 19-9
Cancer progression is often associated with changes in the glycan structures of glycoli-
pids. The glycosyltransferases and glycosidases that act on glycoproteins also act on
glycolipids, resulting in aberrant cancer-associated glycan structures shared by glyco-
proteins and glycolipids. Indeed, once the aberrant cancer-associated glycans in glycoli-
pids are identified, monoclonal antibodies that target the aberrant glycans may be
relatively easy to produce for several reasons: (1) their structures can be elucidated, (2)
glycolipids can be purified to homogeneity, and (3) a purified glycolipid maintains anti-
genicity. For these reasons, aberrant glycans on glycolipids have been extensively stu-
died by the monoclonal antibody approach[56]. In fact, many monoclonal antibodies
directed to human tumor cells or to tissues that show a distinctive reactivity to the
specific type of human cancer have been identified as being directed to glycolipids,
such as N-19-9 antibody for sialyl Lewis
a associated with gastrointestinal/pancreatic
cancers[56,57].
N-19-9 antibody is used in CA 19-9 assay to detect aberrant sialyl Lewis
a glycan.
Because this aberrant glycan is predominantly expressed on mucins in serum from
patients with GI malignancies, it has been used as a cancer biomarker for patients with
GI malignancies. One caveat of using CA 19-9 is that patients known to be genotypi-
cally negative for the Lewis
a blood group antigen will not produce the CA 19-9 anti-
gen–even in the presence of malignant tissue[58]. Another problem with CA 19-9 is
that sialyl Lewis
a glycan is neither a specific product of a specific tumor nor a tumor
only[56]. This problem may be alleviated by using glycoproteomic approaches to iden-
tify glycoproteins accompanying sialyl Lewis
a glycan whose differential expressions are
also associated with a specific type of cancer[59].
Discovery of Cancer Biomarkers Using Glycomic and Glycoproteomic Approaches
Technological advancements in the field of Glycobiology have allowed comprehensive
comparisons of glycans and glycoproteins between normal and tumor cells to identify
differential expression of these cancer-associated glycans and glycoproteins as potential
cancer biomarkers. The glycomic approach uses various methods to release glycans off
glycoproteins or glycolipids and to analyze only the glycans, whereas the glycoproteo-
mic approach separates glycoproteins or fractions of glycoproteins using affinity or
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glycans. Exploiting the difference in glycans and glycoproteins between cancer and nor-
mal cells using glycomic and glycoproteomic approaches provides an opportunity to
discover new biomarkers for personalized cancer diagnosis and treatment.
Cancer Biomarkers Discovered by Glycomic Approaches
Glycomic studies have been carried out to identify changes in serum glycan profiles.
Kyselova et al. [60] compared serum glycan profiles of 10 healthy men and 24 men
with confirmed prostate cancer who were undergoing androgen-deprivation therapy
(ADT) due to cancer metastasis. The sera for these cancer patients were obtained at
the time of starting ADT. This study identified 12 glycan structures that significantly
differentiated between cancerous and normal sera (2 glycans decreased in cancer and
10 increased in cancer) with 6 of the glycans fucosylated and 9 of the glycans sialylated
to a different degree (mono-, di-, and trisialylated structures). Using the same method
in a different study, Kyselova et al. [61] compared the serum glycomic profiles of 27
non-breast cancer women and 82 breast cancer patients in various stages (12 in stage
I, 11 in stage II, 9 in stage III, and 50 in stage IV). Results from this study, including a
heterogeneous population of patients that resembled a true breast cancer population,
showed results similar to the prostate cancer study–that breast cancer progression
appeared to be associated with increased sialylation and fucosylation of glycans in sera.
Changes in serum glycan profiles–demonstrated in prostate, breast, and other types
of cancer–have also been exploited as cancer biomarkers in liver cancer for two rea-
sons: First, the vast majority of glycoproteins in serum are produced by hepatocytes;
second, the asialoglycoprotein receptors and mannose/N-acetylglucosamine (GlcNAc)
receptors in the liver have important roles in the clearance of aberrantly glycosylated
proteins[62]. Thus, changes in the serum N-glycome profile may reflect pathological
changes in the liver.
Multiple non-invasive tests based on serum protein glycomics have been developed
for monitoring liver fibrosis (GlycoFibro test), detecting liver cirrhosis (GlycoCirrho
test), and for screening HCC (GlycoHCC test). All these tests use a DNA sequence
analyzer to generate profiles of the serum protein N-glycans of liver disease patients.
The GlycoFibro test calculates the log ratio between the agalacto glycans (NGA2FB)
and the fully galactosylated triantennary glycans (NA3), which appear to rise gradually
with an increasing fibrosis stage[63]. The GlycoCirrho test can distinguish compen-
sated (early stage) cirrhosis from non-cirrhotic chronic liver disease with 79% sensitiv-
ity and 86% specificity[62]. The GlycoHCC test, using the log ratio of a branch alpha
(1,3)-fucosylated triantennary glycan (elevated in HBV patients with cirrhosis) to a
bisecting core alpha(1,6)-fucosylated biantennary glycan (elevated in HBV patients with
HCC), shows similar sensitivity and specificity to that of AFP in screening HCC from
patients with cirrhosis[64].
Besides serum, glycomic analysis has been applied to cells from culture and tissue
origins. Goetz et al.[65] showed increased fucosylation in O-glycans isolated from inva-
sive cancer cells that could potentially be considered as a measure of breast cancer
invasiveness and tumor progression. Lattova et al.[66] identified glycan changes in
human breast carcinoma cell lines after treatment with Herceptin and Herceptin/Lipo-
plex, which helped study the role of glycosylation during antibody treatment. A
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epithelial cells and colorectal cancer cells that were highly purified with the epithelial
cell marker CD326, Misonou et al. [67] identified three specific alterations in glyco-
sphingolipids in cancer cells compared to normal: increased ratios of type-2 oligosac-
charides, increased a 2-3, and a 2-6 sialylation, and increased a1-2 fucosylation.
Specifically, a shift from type-1 dominant normal colorectal epithelial cells to type-2
dominant colorectal cancer cells was found in five patients with hepatic metastasis.
These cancer-associated glycan structures may be used to discover glycoproteins as
cancer biomarkers for patients with more aggressive cancers and for follow-up of can-
cer progression using the glycoproteomic approaches.
Cancer Biomarkers Discovered by Glycoproteomic Approaches
Glycomic analysis provides direct and structural information of aberrant glycans asso-
ciated with cancer. Such information may also be provided indirectly by studies of the
expression of glycosyltransferases, enzymes involved in the synthesis of glycans. Infor-
mation provided by both direct and indirect approaches has been used in glycoproteo-
mics to identify proteins with aberrant glycosylation in tissue, serum, and cultured
cells as potential cancer biomarkers.
To identify biomarkers for ovarian cancer, Abbott et al.[68] first studied the expres-
sion of glycosyltransferases in endometrioid ovarian tumor tissues using quantitative
real-time PCR and identified increased transcripts of enzymes responsible for core
fucosylation (FUT 8) and bisecting glycans (GnT-III). Assuming that these two glycosy-
lation changes may be related to endometrioid ovarian cancer, Abbott et al. [69] used
lectins AAL and E-PHA to enrich the glycoproteins with core fucosylation and bisect-
ing GlcNAc, respectively, from endometrioid ovarian cancer and non-diseased human
ovary tissues, and identified several glycoproteins with these glycosylation changes that
have higher abundance in cancer than in normal tissues. Among these glycoproteins,
periostin and thrombospondin were validated in tissue and serum using lectin blots,
although only a few samples were used in the validation[69]. Applying a similar
approach to matched normal (non-diseased) and malignant tissue isolated from
patients with invasive ductal breast carcinoma, this group enriched glycoproteins with
increased beta(1,6)-branched N-linked glycans using L-PHA that does not bind to
non-diseased breast epithelial cells, but binds to cells progressed to invasive carcinoma.
This study identified 12 proteins that increased in all 4 matched tumor cases relative
to normal tissues[70], including periostin and haptoglobin-related protein precursor or
haptoglobin.
In serum the most successful story of applying an aberrant glycosylation approach to
discover cancer biomarkers is the use of increased fucosylation for HCC. Using wood-
chucks as the animal model–whose HCC resemble that of human HCC–Block et al.
[71] identified that woodchucks diagnosed with HCC have dramatically higher levels of
serum-associated core a 1,6-linked fucose compared to woodchucks without HCC.
Extending this finding, this group used 2D-gel proteomics to identify glycoproteins
with altered core fucosylation. One such glycoprotein–Golgi Protein 73 (GP73)–not
only elevated and hyperfucosylated in animals with HCC, but also in the serum of
humans with the diagnosis of HCC[72]. Applying a similar 2D-gel proteomic strategy
to human sera, Comunale et al.[73] identified 19 serum proteins to be hyperfucosylated
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firmed in another study by the same group i nac o h o r to f3 0 0s e r u ms a m p l e su s i n g
lectin-based high-throughput plate-based assays were confirmed to have an ROC area
under the curve (AUC) of 0.95 and 0.87, respectively, in the differentiation of HCC
from non-HCC conditions [74]. A separate study from the same group showed that
the combination of fucosylated kininogen, AFP, and GP 73 gave an optimal sensitivity
of 95% at a specificity of 70% and an AUC of 0.94 for identifying patients with HCC
[75]. Nevertheless, the clinical utilities of GP73 are still controversial: Mao et al. [76]
showed that GP73 was an accurate serum marker for detection of HCC and recurrence
after surgery, whereas Yamamoto et al. and Ozkan et al.[77,78] showed that it was not
useful in the diagnosis of HCC, in monitoring treatment response, or in prognosis.
Serum acute-phase reactants were often identified by glycoproteomic approaches to
be the carriers of aberrant glycans associated with cancer. For example, Abd Hamid et
al. [79] demonstrated acute-phase proteins a1-acid glycoprotein, a1-antichymotrypsin,
and the haptoglobin b-chain to be contributors to a 2-fold increase in the monogalac-
tosylated triantennary glycan structure containing alpha1,3-linked fucose in breast can-
cer patients as compared to the controls. Although these serum acute-phase reactants
may be markers of cancer, they are not specific for a type of cancer, nor are the aber-
rant glycosylation of these serum acute-phase reactants. For example, serum concen-
tration of fucosylated haptoglobin has been shown to be increased in prostate, colon,
breast, ovarian, and liver cancers[70,80-83]. Nevertheless, a multiple-marker strategy
combining markers with independent clinical values may still benefit from these mar-
kers that increase the sensitivity but not the specificity for cancer detection[84].
It is well-known that aberrant O-glycans provoke immune responses[85-88]. Serum
autoantibodies against those glycans, therefore, have become another promising area
for discovery of cancer biomarkers. This was made especially feasible by development
of the chemoenzymatic synthesis of O-glycopeptides. Using microarrays deposited with
the synthesized O-glycopeptides, Wandall et al. [89] screened for autoantibodies gener-
ated to aberrant glycoforms of MUC1 as cancer biomarkers for early detection of
breast, ovarian, and prostate cancers. Similarly, Wang et al.[90] used glycan microar-
rays comprised of Globo H, a cancer-associated carbohydrate antigen highly expressed
on breast cancer cells and other related structures, for quantitative analysis of their
respective autoantibodies present in the plasma of breast cancer patients and normal
blood donors. This study showed that the amount of autoantibodies against Globo H
from breast cancer patients were significantly higher than normal blood donors, pro-
viding a new tool for possible breast cancer diagnosis[90].
Besides tissue and serum, cell lines offer good models to discover cancer biomarkers.
Dai et al. [91] identified aberrantly a1,6-fucosylated glycoproteins related to hepatocel-
lular carcinoma (HCC) metastasis in MHCC97-H and MHCC97-L cells with high and
low metastatic potentials. This study implied that the alteration of CK8, annexin I, and
annexin II both in their expression levels and in their glycan parts might be related to
metastatic ability, and may also play a critical role in the process of HCC metastasis.
HT-29 human colon epithelial cancer cells are a cellular model of colon cancer pro-
gression, as they can either proliferate or differentiate into enterocyte phenotype. Ver-
coutter-Edouart et al. [92] identified membrane-bound N-glycoproteins from HT-29
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proteins contributed by solute carrier family and adhesion proteins.
A glycoproteomic approach has also been used to identify predictive cancer biomar-
kers. Although the majority of advanced ovarian carcinomas initially respond to che-
motherapy, a significant portion of them fail to respond successfully to further
treatments. Chemoresistance thus represents a major obstacle in attempts to improve
clinical outcome. The high prevalence and poor prognosis of ovarian cancer emphasize
the need to identify prognostic markers that can be used to select patients to receive
new, individualized therapies. One cause of chemoresistance in human cancer may be
the elevated expression or activity of ATP-binding cassette transporters. Glycoproteo-
mic analysis of paclitaxel-sensitive and resistant human epithelial ovarian cancer cell
lines identified putative biomarkers that were remarkably upregulated in resistant cell
lines and may represent biomarkers for paclitaxel resistance in ovarian cancer[93].
Cancer Biomarkers Discovered by Functional Glycoproteomic Approaches
Glycoproteins with aberrant glycosylation that are differentially expressed in normal
and cancer cells–for which we have given a few examples in the previous section–may
be used as cancer biomarkers. But functionally it is unknown how these proteins are
responsible for cancer progression. A functional glycoproteomic approach could help
answer this question by (1) identifying target proteins of these glycosyltransferase
genes implicated in cancer, using the glycosyltransferase gene knockout or knockdown
cell models and (2) identifying the functional roles of these aberrant glycosylated pro-
teins in cancer cell invasion and metastasis in vivo and in vitro. Glycoproteins with
aberrant glycosylation that are functionally responsible for cancer progression are more
likely to be used as cancer biomarkers.
Examples of glycoproteins with aberrant glycans implicated in cancer progression
include tissue inhibitors of metalloproteinase-1, identified as target proteins of N-acet-
ylglucosamine transferase V (GlcNAcT-V). The tissue inhibitor of metalloproteinase-1
(TIMP-1) is an endogenous inhibitor of matrix metalloproteinase that plays a critical
role in invasion, migration, and malignant transformation of cancer cells. The aberrant
glycans on TIMP-1, induced by GlcNAcT-V, may affect the properties of binding with
gelatinases, presumably by conferring a steric hindrance arising from the massiveness
of glycosylation and an electrostatic repulsion arising from the attachment of acidic
residues to the binding to gelatinases[94,95]. Because of the functional role of aberrant
glycosylation of TIMP-1, Ahn et al. [96] generated antibodies recognizing an aberrant
glycoform of TIMP-1. Such efforts will be very helpful in the development of immune-
based assays to evaluate the clinical performance and utilities of aberrant glycoforms of
TIMP-1 in a personalized approach to cancer diagnosis and treatment.
Conclusions
Cancer biomarkers could be the driving force in the personalized approach to cancer
diagnosis and treatment. As a hallmark of cancer, aberrant glycosylation allows for the
rational design of biomarker discovery research. First, changes in glycosylation machin-
ery such as glycosyltransferases/glycosidases could be used as cancer biomarkers. Sec-
ond, differential expression of these enzymes in the compared cancer cells may point
to specific cancer-associated aberrations in glycan structures. In the case of AFP-L3,
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fucosyltransferase in hepatoma tissues[97]. Therefore, cancer-associated aberrations in
glycan structures can be used to improve on existing cancer biomarkers, most of
which are glycoprotein. Furthermore, cancer-associated aberrations in glycan structures
provide a compelling rationale for the discovery of new biomarkers through the isola-
tion and identification of glycoproteins that contain these glycan structures.
There is no doubt that we need to develop glycomic and glycoproteomic technolo-
gies with higher throughput and better sensitivity, specificity, and reproducibility. More
important, we need to translate these biomarkers into clinical diagnostics[19]. Subject-
ing them through a vigorous validation process using high-quality, well-annotated clin-
ical specimens is necessary. And availability of large serum banks that could provide
such specimens, therefore, will help facilitate the translation of biomarkers from dis-
covery into clinical diagnostics.
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